Global hemophilia treatment market is inclined to accumulate substantial returns over the ensuing years owing to the rising cases of genetic abnormalities and increasing prevalence of hemophilia. Hemophilia is a rare bleeding disorder, which causes incessant or prolonged bleeding after an injury or surgery due to delayed blood clotting. Quality care and efficient treatment can help prevent some serious consequences of the disorder.
Development of advanced treatment technologies such as hemophilia gene therapy is slated to further augment market growth in the succeeding years. Biotechnology companies have been particularly proactive in this regard, working on investigational gene therapies for patients with severe hemophilia A. Successful execution and approval of hemophilia gene therapy will have a substantial effect on hemophilia treatment market size in the future.
Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/2772
Based on product, the recombinant factor concentrates segment is poised to exhibit a growth rate of 5% through 2025, as a result of low disease transmission risks and its prevention of viral infection. Additionally, the product is capable of increasing the replacement therapy safety.
The global hemophilia treatment market from the adult segment recorded revenue worth $6,778.2 million in 2018, as adult patients have high chances of developing moderate to severe hemophilia. As per authentic reports, over 65% of the patients diagnosed with hemophilia are adults.
With regards to the treatment spectrum, the global hemophilia treatment market from the prophylaxis treatment segment registered remuneration of $7,219.9 million in 2018 and is set to account for a major market share over the forecast spell, which can be credited to its effectiveness in treating bleeding episodes and joint pain.
Based on end-use, the hemophilia treatment centers segment is poised to register a growth rate of 4.6% through 2025, which can be attributed to the enhanced care services provided by these centers as compared to clinics and hospitals.
Major industry players have executed several growth strategies such as collaborations, new launches, and mergers to reinforce their position in the global hemophilia treatment market. In 2017, patients with hemophilia A received a more long-lasting option with Roche’s Hemlibra. The drug received approval from Health Canada for hemophilia A patients deprived of factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce its frequency. Increasing demand for Roche’s Hemlibra and similar medications among hemophilia A patients would escalate hemophilia treatment industry share.
The competitive landscape of the hemophilia treatment market comprises of companies such as Genentech, Biotest AG, Swedeish Orphan Biovitrum AB, and Sanofi SA, among others. These firms are focusing on expanding their stance in the global market through various strategies including partnerships and innovative product launches.
Request for customization @ https://www.gminsights.com/roc/2772
Partial Chapter of the Table of Content
Chapter 5. Hemophilia Treatment Market, By Product
5.1. Global market share by product, 2018 & 2025
5.2. Recombinant Factor Concentrates
5.2.1. Market size, by region, 2014 – 2025 (USD Million)
5.2.2. Factor VIII
188.8.131.52. Market size, by region, 2014 – 2025 (USD Million)
5.2.3. Factor IX
184.108.40.206. Market size, by region, 2014 – 2025 (USD Million)
5.3. Plasma-derived Factor Concentrates
5.3.1. Market size, by region, 2014 – 2025 (USD Million)
5.3.2. Factor VIII
220.127.116.11. Market size, by region, 2014 – 2025 (USD Million)
5.3.3. Factor IX
18.104.22.168. Market size, by region, 2014 – 2025 (USD Million)
5.4. Extended Half-life Products
5.4.1. Market size, by region, 2014 – 2025 (USD Million)
5.4.2. Factor VIII
22.214.171.124. Market size, by region, 2014 – 2025 (USD Million)
5.4.3. Factor IX
126.96.36.199. Market size, by region, 2014 – 2025 (USD Million)
5.5.1. Market size, by region, 2014 – 2025 (USD Million)
Browse full table of contents (TOC) of this report @ https://www.gminsights.com/toc/detail/hemophilia-treatment-market